Evidence map›Paper›PMID 36909640›Full record

ArticlebioRxiv : the preprint server for biology2023

Screening in serum-derived medium reveals differential response to compounds targeting metabolism.

Keene L Abbott, Ahmed Ali, Dominick Casalena, Brian T Do, Raphael Ferreira, Jaime H Cheah, Christian K Soule, Amy Deik, Tenzin Kunchok, Daniel R Schmidt and 20 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 12 institutions in 4 countries.

Keene L AbbottKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Ahmed AliKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Dominick CasalenaNovartis Institute for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
Brian T DoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Raphael FerreiraDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Jaime H CheahKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Christian K SouleKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Amy DeikBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Tenzin KunchokWhitehead Institute for Biomedical Research, Cambridge, MA 02139, USA.
Daniel R SchmidtKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Steffen RennerNovartis Institutes for BioMedical Research, 4056 Basel, Switzerland.
Sophie E HonederKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Michelle WuKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Sze Ham ChanWhitehead Institute for Biomedical Research, Cambridge, MA 02139, USA.
Tenzin TseyangWhitehead Institute for Biomedical Research, Cambridge, MA 02139, USA.
Daniel GreavesCambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge CB2 0AW, UK.
Peggy P HsuKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Christopher W NgKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Chelsea J ZhangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Ali FarsidjaniNovartis Institute for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
Iva Monique T GramatikovKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Nicholas J MathesonKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Caroline A LewisWhitehead Institute for Biomedical Research, Cambridge, MA 02139, USA.
Clary B ClishBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Matthew G ReesBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jennifer A RothBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Lesley Mathews GrinerNovartis Institute for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
Alexander MuirBen May Department of Cancer Research, University of Chicago, Chicago, IL, USA.
Douglas S AuldNovartis Institute for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Broad Institute · USNovartis (United States) · USWhitehead Institute for Biomedical Research · USMassachusetts Institute of Technology · USBeth Israel Deaconess Medical Center · USUniversity of Cambridge · GBHarvard–MIT Division of Health Sciences and Technology · USHarvard University · USMassachusetts General Hospital · USMedical University of Graz · ATNovartis (Switzerland) · CHUniversity of Chicago · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
PRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8M
Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI MUCCI, LORELEI · 2002 to 2017
$36.2M
Training Program in Cancer Biology and TherapeuticsT32CA071345 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber, Lecia V. Sequist · 1997 to 2026
$10.6M
Institutional Career Development CoreKL2TR002542 · NCATS · HARVARD MEDICAL SCHOOL · PI BREDELLA, MIRIAM ANTOINETTE, RUTKOVE, SEWARD B. · 2018 to 2022
$8.7M
Understanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8M
Molecular determinants of fetal hemoglobin induction by hydroxyurea to treat sickle cell diseaseF30HL156404 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI DO, BRIAN TSHAO · 2021 to 2023
$155k
Exploiting metabolic vulnerabilities of breast cancer brain metastases for therapyF31CA271787 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABBOTT, KEENE · 2022 to 2023
$94k
NCATS NIH HHS KL2 TR002542NCI NIH HHS F31 CA271787NCI NIH HHS P50 CA090381NCI NIH HHS R35 CA242379NCI NIH HHS T32 CA071345NHLBI NIH HHS F30 HL156404NIGMS NIH HHS T32 GM007287NIGMS NIH HHS T32 GM007753Wellcome Trust
6 · The paper itself

Abstract

A challenge for screening new candidate drugs to treat cancer is that efficacy in cell culture models is not always predictive of efficacy in patients. One limitation of standard cell culture is a reliance on non-physiological nutrient levels to propagate cells. Which nutrients are available can influence how cancer cells use metabolism to proliferate and impact sensitivity to some drugs, but a general assessment of how physiological nutrients affect cancer cell response to small molecule therapies is lacking. To enable screening of compounds to determine how the nutrient environment impacts drug efficacy, we developed a serum-derived culture medium that supports the proliferation of diverse cancer cell lines and is amenable to high-throughput screening. We used this system to screen several small molecule libraries and found that compounds targeting metabolic enzymes were enriched as having differential efficacy in standard compared to serum-derived medium. We exploited the differences in nutrient levels between each medium to understand why medium conditions affected the response of cells to some compounds, illustrating how this approach can be used to screen potential therapeutics and understand how their efficacy is modified by available nutrients.

Identifiers

PMID36909640
PMCPMC10002634
OpenAlexW4322490302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.